J&J posts a solid round of positive early data for their BCMA/CD3 bispecific teclistamab, highlighting blockbuster expectations
J&J’s oncology R&D team has posted promising early data on one of its blockbuster drug candidates in the pipeline.
JNJ-7957, their BCMA/CD3 bispecific now called teclistamab, hit a 67% overall response rate among the 12 patients with multiple myeloma who received the highest dose available in their Phase I trial. Among those 8 of 12 patients, 3 achieved a complete response, with no visible sign of the disease.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,900+ biopharma pros reading Endpoints daily — and it's free.